男性性腺機能低下症の世界市場レポート 2024年

男性性腺機能低下症市場規模は近年力強く成長しています。2023年の35億5,000万米ドルから2024年には38億米ドルへと、CAGR6.8％で拡大します。過去の期間における成長は、人口の高齢化、認識と診断の増加、ライフスタイル要因、慢性疾患の有病率、治療を求める行動パターンなどの要因に起因しています。

男性性腺機能低下症市場規模は、今後数年間で力強い成長が見込まれます。2028年にはCAGR5.9％で47億7,000万米ドルに成長します。今後予測される増加は、意識の高まり、ライフスタイルに関連した疾患の流行、治療法の進歩、男性の健康への注目、遠隔医療やヘルスケアへのアクセスの改善などに起因しています。予測期間中に予想される注目すべき動向には、心理的・性的健康への重点の高まり、栄養補助食品や生活習慣への介入の探求、新興国における市場の拡大、共同研究の取り組み、長期的な安全性とモニタリングへの重点の高まりなどが含まれます。

予測される不妊率の上昇は、今後の男性性腺機能低下症市場の拡大を牽引するものと思われます。不妊症は、避妊をしない性行為を12ヶ月以上繰り返しても妊娠できない状態と定義され、男性・女性両方の生殖器系に影響を及ぼします。男性性腺機能低下症は、精子生産の低下と不妊症の潜在的な原因であり、普及率の増加が予想され、男性性腺機能低下症市場の成長をさらに促進します。特に、北米の国立衛生研究所（NIH）の2023年3月時点のデータでは、男性不妊率は4.5～6％、オーストラリアでは9％、東欧では8～12％と推定されています。さらに、2021年のLibyan Journal of Medical Sciences誌の研究では、リビアにおける不妊症の約70％は男性要因によるものであり、この文脈における男性性腺機能低下症の役割が強調されています。

慢性疾患の増加は、男性性腺機能低下症市場成長の原動力になると予想されます。慢性疾患は1年以上続き、継続的な医学的治療を必要とするため、ホルモン産生経路に大きな影響を与え、テストステロンの合成と調節に影響を与えるため、男性性腺機能低下症の発生が増加します。例えば、2023年1月に米国国立生物工学情報センター（NCBI）が発表した予測では、2020年には7,152万2,000人であった50歳以上の慢性疾患患者が、2050年には1億4,266万人に達し、大幅に増加することが示唆されています。その結果、慢性疾患の有病率の上昇が男性性腺機能低下症市場の拡大に寄与すると予想されます。

2023年の男性性腺機能低下症市場では北米が最大地域でした。アジア太平洋は、男性性腺機能低下症市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。男性性腺機能低下症市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 男性性腺機能低下症市場の特徴

第3章 男性性腺機能低下症市場の動向と戦略

第4章 男性性腺機能低下症市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の男性性腺機能低下症市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 男性性腺機能低下症市場セグメンテーション

• 世界の男性性腺機能低下症市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• クラインフェルター症候群
• カルマン症候群
• 下垂体疾患
• その他のタイプ
• 世界の男性性腺機能低下症市場、ドラッグデリバリー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 局所ジェル
• 注射剤
• 経皮パッチ
• その他の医薬品の配達
• 世界の男性性腺機能低下症市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• テストステロン療法
• ゴナドトロピン放出ホルモン療法

第7章 男性性腺機能低下症市場の地域および国分析

• 世界の男性性腺機能低下症市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の男性性腺機能低下症市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の男性性腺機能低下症市場

第9章 中国男性性腺機能低下症市場

第10章 インド男性性腺機能低下症市場

第11章 日本の男性性腺機能低下症市場

第12章 オーストラリア男性性腺機能低下症市場

第13章 インドネシア男性性腺機能低下症市場

第14章 韓国男性性腺機能低下症市場

第15章 西欧男性性腺機能低下症市場

第16章 英国男性性腺機能低下症市場

第17章 ドイツ男性性腺機能低下症市場

第18章 フランス男性性腺機能低下症市場

第19章 イタリア男性性腺機能低下症市場

第20章 スペイン男性性腺機能低下症市場

第21章 東欧男性性腺機能低下症市場

第22章 ロシア男性性腺機能低下症市場

第23章 北米男性性腺機能低下症市場

第24章 米国男性性腺機能低下症市場

第25章 カナダ男性性腺機能低下症市場

第26章 南米男性性腺機能低下症市場

第27章 ブラジル男性性腺機能低下症市場

第28章 中東男性性腺機能低下症市場

第29章 アフリカ男性性腺機能低下症市場

第30章 男性性腺機能低下症市場の競合情勢と企業プロファイル

• 男性性腺機能低下症市場の競合情勢
• 男性性腺機能低下症市場の企業プロファイル
  • Allergan plc
  • Pfizer Inc.
  • Bayer AG
  • Eli Lilly and Company Ltd.
  • Endo International plc.

第31章 世界の男性性腺機能低下症市場の競合ベンチマーキング

第32章 世界の男性性腺機能低下症市場競争力ダッシュボード

第33章 男性性腺機能低下症市場における主要な合併と買収

第34章 男性性腺機能低下症市場の将来展望と可能性分析

第35章 付録

“Male Hypogonadism Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on male hypogonadism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for male hypogonadism? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The male hypogonadism market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Klinefelters Syndrome; Kallmann Syndrome; Pituitary Disorders; Other Types
• 2) By Drug Delivery: Topical Gels; Injectables; Transdermal Patches; Other Drug Deliveries
• 3) By Therapy: Testosterone Therapy; Gonadotropin-Releasing Hormone Therapy
• Companies Mentioned: Allergan plc; Pfizer Inc.; Bayer AG; Eli Lilly and Company Ltd.; Endo International plc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Male hypogonadism is a condition characterized by insufficient production of the hormone testosterone in the body. Testosterone plays a crucial role as the primary male sex hormone, and its presence is vital for the development and growth of men during puberty.

The main types of male hypogonadism include Klinefelter syndrome, Kallmann syndrome, pituitary disorders, and others. Klinefelter syndrome is a hereditary disorder that manifests in boys when they have an extra copy of the X chromosome at birth. Treatment for male hypogonadism often involves testosterone therapy delivered through various methods such as topical gels, injectables, transdermal patches, and gonadotropin-releasing hormone therapy.

The male hypogonadism market research report is one of a series of new reports from The Business Research Company that provides male hypogonadism market statistics, including male hypogonadism industry global market size, regional shares, competitors with a male hypogonadism market share, detailed male hypogonadism market segments, market trends, and opportunities, and any further data you may need to thrive in the male hypogonadism industry. This male hypogonadism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The male hypogonadism market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historic period can be attributed to factors such as an aging population, increased awareness and diagnosis, lifestyle factors, the prevalence of chronic illnesses, and the patterns of treatment-seeking behavior.

The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $4.77 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The increase projected for the upcoming period can be ascribed to the heightened awareness, the prevalence of lifestyle-related conditions, advancements in therapies, a focus on men's health, and improved accessibility to telemedicine and healthcare. Notable trends expected in the forecast period encompass a heightened emphasis on psychological and sexual health, the exploration of nutraceuticals and lifestyle interventions, the expansion of markets in emerging economies, collaborative research initiatives, and an increased focus on long-term safety and monitoring.

The anticipated rise in infertility rates is poised to drive the expansion of the male hypogonadism market in the future. Infertility, defined as the inability to conceive after 12 months or more of frequent, unprotected sexual activity, affects both male and female reproductive systems. Male hypogonadism, a potential contributor to reduced sperm production and infertility, is expected to witness increased prevalence, further fueling the growth of the male hypogonadism market. Notably, data from the National Institutes of Health (NIH) in North America, as of March 2023, indicates male infertility rates estimated at 4.5% - 6%, 9% in Australia, and possibly ranging from 8% to 12% in Eastern Europe. Additionally, a 2021 study in the Libyan Journal of Medical Sciences attributes around 70% of infertility cases in Libya to male factors, underscoring the role of male hypogonadism in this context.

The escalating incidence of chronic diseases is anticipated to be a driving force behind the male hypogonadism market's growth. Chronic diseases, lasting a year or more and requiring continuous medical attention, significantly impact hormone production pathways, leading to an elevated occurrence of male hypogonadism due to their effects on testosterone synthesis and regulation. For example, projections from the National Center for Biotechnology Information (NCBI) in January 2023 suggest a substantial surge, reaching 142.66 million individuals aged 50 and older with at least one chronic illness by 2050, compared to 71.522 million in 2020. Consequently, the rising prevalence of chronic diseases is expected to contribute to the expansion of the male hypogonadism market.

A prominent trend is the increasing popularity of product innovations. Companies within this sector are actively pursuing the development of novel products to maintain their competitive positions. For example, in June 2022, Halozyme, a biotechnology company based in the United States, introduced Tlando, an oral treatment designed for testosterone replacement therapy in male hypogonadism. Tlando, a prescription drug containing testosterone, represents a milestone as the first FDA-approved oral testosterone treatment. Its application is targeted at adult men experiencing low or no testosterone due to specific medical conditions.

Major players in the male hypogonadism market are strategically directing their efforts toward creating innovative products, including digital-forward platforms. These platforms aim to engage patients through telemedicine, provide educational resources, and simplify access to treatments, thereby revolutionizing the care landscape for male hypogonadism while enhancing patient support and treatment accessibility. An illustrative example is Base Healthcare, a U.S.-based men's virtual health platform, which, in October 2022, launched a subscription-based platform exclusively for men. This digital health platform prioritizes fundamental health and hormone enhancement through oral testosterone treatment, offering users convenient access to adequate testosterone therapy (ATT), certified medical professionals, and personalized health guidance.

In July 2022, Gruenenthal, a pharmaceutical company headquartered in Germany, acquired Nebido from Bayer AG for €500 million ($551.32 million). This acquisition is strategically aimed at enhancing Gruenenthal's profitability and enabling increased investment in research and development to pave the way for the next generation of pain therapies. Bayer AG, a renowned German pharmaceutical company, plays a pivotal role in the male hypogonadism treatment sector, further influencing the market landscape.

Major companies operating in the male hypogonadism market report are Allergan plc, Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc., Merck & Co. Inc., Ferring Pharmaceuticals, Finox Biotech AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Perrigo Company plc, AstraZeneca plc, IBSA Institut Biochimique SA, Juniper Laboratories SA, Sun Pharmaceutical Industries Limited, Glenmark Pharmaceuticals Limited, Antares Pharma Inc., Zydus Cadila LLC, Besins Healthcare Ltd., Clarus Therapeutics Holdings Inc., Endocrine Technologies Inc., Foresee Pharmaceuticals Co. Ltd., Lipocine Inc., Mereo BioPharma Group plc, Myovant Sciences Ltd., Novartis AG, Novo Nordisk A/S, Repros Therapeutics Inc., Sandoz International GmbH, Sanofi SA, Sermonix Pharmaceuticals LLC, Shionogi & Co. Ltd., Solvay SA, TherapeuticsMD Inc., Viking Therapeutics Inc

North America was the largest region in the male hypogonadism market in 2023. Asia-Pacific is expected to be the fastest-growing region in the male hypogonadism market report during the forecast period. The regions covered in the male hypogonadism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the male hypogonadism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The male hypogonadism market includes revenues earned by entities through hormone testing, semen analysis, pituitary imaging, genetic studies, and testicular biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Male Hypogonadism Market Characteristics

3. Male Hypogonadism Market Trends And Strategies

4. Male Hypogonadism Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Male Hypogonadism Market Size and Growth

• 5.1. Global Male Hypogonadism Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Male Hypogonadism Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Male Hypogonadism Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Male Hypogonadism Market Segmentation

• 6.1. Global Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Klinefelters Syndrome
• Kallmann Syndrome
• Pituitary Disorders
• Other Types
• 6.2. Global Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Topical Gels
• Injectables
• Transdermal Patches
• Other Drug Deliveries
• 6.3. Global Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Testosterone Therapy
• Gonadotropin-Releasing Hormone Therapy

7. Male Hypogonadism Market Regional And Country Analysis

• 7.1. Global Male Hypogonadism Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Male Hypogonadism Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Male Hypogonadism Market

• 8.1. Asia-Pacific Male Hypogonadism Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Male Hypogonadism Market

• 9.1. China Male Hypogonadism Market Overview
• 9.2. China Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Male Hypogonadism Market

• 10.1. India Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Male Hypogonadism Market

• 11.1. Japan Male Hypogonadism Market Overview
• 11.2. Japan Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Male Hypogonadism Market

• 12.1. Australia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Male Hypogonadism Market

• 13.1. Indonesia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Male Hypogonadism Market

• 14.1. South Korea Male Hypogonadism Market Overview
• 14.2. South Korea Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Male Hypogonadism Market

• 15.1. Western Europe Male Hypogonadism Market Overview
• 15.2. Western Europe Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Male Hypogonadism Market

• 16.1. UK Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Male Hypogonadism Market

• 17.1. Germany Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Male Hypogonadism Market

• 18.1. France Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Male Hypogonadism Market

• 19.1. Italy Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Male Hypogonadism Market

• 20.1. Spain Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Male Hypogonadism Market

• 21.1. Eastern Europe Male Hypogonadism Market Overview
• 21.2. Eastern Europe Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Male Hypogonadism Market

• 22.1. Russia Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Male Hypogonadism Market

• 23.1. North America Male Hypogonadism Market Overview
• 23.2. North America Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Male Hypogonadism Market

• 24.1. USA Male Hypogonadism Market Overview
• 24.2. USA Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Male Hypogonadism Market

• 25.1. Canada Male Hypogonadism Market Overview
• 25.2. Canada Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Male Hypogonadism Market

• 26.1. South America Male Hypogonadism Market Overview
• 26.2. South America Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Male Hypogonadism Market

• 27.1. Brazil Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Male Hypogonadism Market

• 28.1. Middle East Male Hypogonadism Market Overview
• 28.2. Middle East Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Male Hypogonadism Market

• 29.1. Africa Male Hypogonadism Market Overview
• 29.2. Africa Male Hypogonadism Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Male Hypogonadism Market, Segmentation By Drug Delivery, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Male Hypogonadism Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Male Hypogonadism Market Competitive Landscape And Company Profiles

• 30.1. Male Hypogonadism Market Competitive Landscape
• 30.2. Male Hypogonadism Market Company Profiles
  • 30.2.1. Allergan plc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Pfizer Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bayer AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Eli Lilly and Company Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Endo International plc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Male Hypogonadism Market Competitive Benchmarking

32. Global Male Hypogonadism Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Male Hypogonadism Market

34. Male Hypogonadism Market Future Outlook and Potential Analysis

• 34.1 Male Hypogonadism Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Male Hypogonadism Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Male Hypogonadism Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer